Related Experiment Video
Updated: Jun 23, 2026

08:47
Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells
Published on: May 1, 2020
Crystallization of eIF4E complexed with eIF4GI peptide and glycerol reveals distinct structural differences around
Christopher J Brown1, Chandra S Verma, Malcolm D Walkinshaw
1Institute of Molecular and Cell Biology (A-STAR), Proteos, Singapore.
Cell Cycle (Georgetown, Tex.)
|May 15, 2009
Summary
Structural insights into the eukaryotic translation initiation factor 4E (eIF4E) reveal a novel conformation with bound glycerol. This structure, potentially an intermediate state, offers new avenues for designing eIF4E inhibitors for cancer therapy.
Area of Science:
- Structural Biology
- Molecular Biology
- Biochemistry
Background:
- The eukaryotic translation initiation factor 4E (eIF4E) plays a crucial role in cap-dependent translation initiation.
- Dysregulation of eIF4E is implicated in various cancers, making it a therapeutic target.
Purpose of the Study:
- To elucidate the structural basis of eIF4E's interaction with its cap-binding site.
- To identify potential intermediate states of eIF4E that could be targeted for drug design.
Main Methods:
- X-ray crystallography was employed to determine the structure of the eIF4E peptide complex.
- Comparative structural analysis was performed on eIF4E complexes with and without bound ligands.
Main Results:
- Two distinct eIF4E complexes were observed in the asymmetric unit: one bound to m(7)GTP and another with bound glycerol.
- Significant structural differences in the cap-binding site were noted between the two complexes.
- The glycerol-bound structure revealed a novel conformation with reoriented side chains and a displaced water molecule, hypothesized as an intermediate state.
Conclusions:
- The identified glycerol-bound conformation of eIF4E represents a potential intermediate state between apo and ligand-bound forms.
- These structural findings provide valuable insights for the rational design of novel eIF4E inhibitors for cancer therapy.

